Trial Profile
Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Pimivalimab (Primary)
- Indications Advanced breast cancer; Gastric cancer; Mesothelioma; Neuroendocrine carcinoma; Oesophageal cancer; Ovarian cancer; Pelvic cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jounce Therapeutics
- 28 Apr 2023 Status changed from active, no longer recruiting to completed.
- 09 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 14 May 2021 Planned End Date changed from 1 May 2021 to 1 Aug 2022.